SCA
AEMD icon

Sassicaia Capital Advisers’s Aethlon Medical AEMD Stock Holding History

Sassicaia Capital Advisers’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-450
Closed -$31K – 28
2024
Q4 		$31K Buy
+450
New +$15.3K 0.75% 6

Other funds holding AEMD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
AFGAS
Allegiance Financial Group Advisory Services Vienna, Virginia $503M AUM 22.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Sassicaia Capital Advisers's AEMD Position: Q1 2025 in Review

Sassicaia Capital Advisers sold out of Aethlon Medical (AEMD) in Q1 2025, closing a stake of 450 shares — an estimated $31K sold.

Sassicaia Capital Advisers first reported a position in AEMD in Q4 2024 and held it in 1 quarter. The position peaked at $31K in Q4 2024. 19 funds tracked by Wall St. Rank hold AEMD as of Q1 2025.

  • Sassicaia Capital Advisers reported no remaining Aethlon Medical position as of Q1 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 450 Aethlon Medical shares in Q1 2025, an estimated $31K.
  • Sassicaia Capital Advisers first reported a position in Aethlon Medical in Q4 2024 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Aethlon Medical position peaked at $31K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Aethlon Medical as of Q1 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2025, filed 15 May 2025.